ELEV icon

Elevation Oncology

0.2475 USD
-0.0116
4.48%
At close Apr 1, 4:00 PM EDT
After hours
0.2450
-0.0025
1.01%
1 day
-4.48%
5 days
-12.54%
1 month
-48.33%
3 months
-58.41%
6 months
-55.84%
Year to date
-58.41%
1 year
-95.04%
5 years
-97.84%
10 years
-97.84%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 13

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

4% more funds holding

Funds holding: 68 [Q3] → 71 (+3) [Q4]

10.2% less ownership

Funds ownership: 77.82% [Q3] → 67.61% (-10.2%) [Q4]

19% less capital invested

Capital invested by funds: $27.6M [Q3] → $22.5M (-$5.11M) [Q4]

50% less call options, than puts

Call options by funds: $1K | Put options by funds: $2K

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$0.70
183%
upside
Avg. target
$2.94
1,088%
upside
High target
$7
2,728%
upside

5 analyst ratings

positive
20%
neutral
80%
negative
0%
Stephens & Co.
Sudan Loganathan
22% 1-year accuracy
6 / 27 met price target
1,920%upside
$5
Equal-Weight
Downgraded
24 Mar 2025
Piper Sandler
Biren Amin
17% 1-year accuracy
4 / 24 met price target
183%upside
$0.70
Neutral
Downgraded
21 Mar 2025
Citizens Capital Markets
Silvan Tuerkcan
19% 1-year accuracy
10 / 53 met price target
2,728%upside
$7
Market Perform
Downgraded
21 Mar 2025
Leerink Partners
Andrew Berens
20% 1-year accuracy
1 / 5 met price target
304%upside
$1
Market Perform
Downgraded
21 Mar 2025
HC Wainwright & Co.
Swayampakula Ramakanth
22% 1-year accuracy
45 / 203 met price target
304%upside
$1
Buy
Maintained
21 Mar 2025

Financial journalist opinion

Based on 5 articles about ELEV published over the past 30 days

Neutral
PRNewsWire
1 week ago
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
-- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers -- -- On-track to file an Investigational New Drug (IND) application in 2026 – BOSTON , March 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois. EO-1022 is an antibody drug conjugate (ADC) containing seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody (mAb), which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4.
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Negative
Zacks Investment Research
1 week ago
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Negative
Benzinga
1 week ago
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
Neutral
PRNewsWire
1 week ago
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation --  -- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in 2026 -- -- Updated clinical data of Claudin 18.2 ADC EO-3021 demonstrate ORR of 22.2% in biomarker-enriched patient population; electing to discontinue further development of EO-3021 -- -- Implementing workforce reduction of approximately 70%; cash runway extended into 2H 2026 -- BOSTON , March 20, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug conjugate (ADC), which Elevation Oncology was developing for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers.
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
Neutral
PRNewsWire
3 weeks ago
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
-- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer -- -- Expect to report initial data from combination cohorts in 4Q 2025 or 1Q 2026 -- -- On-track to report additional monotherapy data from dose escalation and expansion cohort of ongoing Phase 1 clinical trial in 2Q 2025 -- -- Preclinical data for HER3 ADC EO-1022 to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025; plan to file an Investigational New Drug (IND) application in 2026 -- BOSTON , March 6, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2024, and highlighted recent business achievements. "We continue to advance our Claudin 18.2 ADC program, EO-3021, for the treatment of advanced gastric/GEJ cancer in the earlier lines settings," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Neutral
PRNewsWire
1 month ago
Elevation Oncology to Participate in Upcoming Investor Conferences
BOSTON , Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference. Fireside chat on Tuesday, March 4, 2025 at 9:10 AM ET in Boston, MA.
Elevation Oncology to Participate in Upcoming Investor Conferences
Neutral
PRNewsWire
2 months ago
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer --  -- Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 -- -- On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoing Phase 1 clinical trial in 1H 2025 -- -- Plan to present preclinical data for HER3 ADC EO-1022 in 1H 2025 and file an Investigational New Drug (IND) application in 2026 --  BOSTON , Jan. 13, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming milestones. "We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Neutral
PRNewsWire
3 months ago
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload -- – Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 – BOSTON , Dec. 12, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
Neutral
PRNewsWire
3 months ago
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologies AMSTERDAM , Dec. 12, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has entered into a licensing agreement with Elevation Oncology, Inc., an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
Neutral
PRNewsWire
3 months ago
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer – -- On-track to initiate dosing in combination portion of the ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024 -- BOSTON , Dec. 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating the combination potential of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC), with VEGFR2 or PD-1 inhibitors. The data will be presented in a poster session at the European Society for Medical Oncology Immuno-Oncology Annual Congress 2024 (ESMO-IO), being held December 11-13, 2024, in Geneva, Switzerland.
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
Charts implemented using Lightweight Charts™